SPAC17H9.07 Antibody

Antibody Characterization

Target: Sup11p (encoded by SPAC17H9.07)
Organism: Schizosaccharomyces pombe
Function:

• Essential for β-1,6-glucan biosynthesis .

• Required for proper septum assembly during cytokinesis .

• Hypo-mannosylated in O-mannosylation-deficient mutants, with unusual N-glycosylation observed .

Antigen Properties:

Key Research Applications

The SPAC17H9.07 antibody has been employed in:

• Western blotting: Detection of Sup11p in cell lysates under denaturing conditions .

• Immunofluorescence: Visualization of Sup11p localization during septum formation .

• Functional studies: Characterization of sup11+ knockdown mutants (e.g., nmt81-sup11), revealing β-1,6-glucan deficiency and septation defects .

Genetic Essentiality

• SPAC17H9.07 is an essential gene; its depletion leads to cell lethality due to disrupted β-1,6-glucan synthesis .

• Mutants show:

  • Accumulation of aberrant β-1,3-glucan deposits in septa .

  • Dysregulated expression of glucanases (e.g., gas2+) and glucan synthases .

Phenotypic Analysis of nmt81-sup11 Mutants

Technical Protocols

Western Blot Conditions:

• Primary Antibody: Anti-Sup11p (polyclonal, affinity-purified) .

• Dilution: 1:1,000 in 5% BSA/TBS-T .

• Detection: Chemiluminescence with HRP-conjugated secondary antibodies .

Microarray Data:

• sup11+ knockdown triggers significant differential expression of 42 genes (FDR < 0.05), including glucanases and synthases .

Clinical and Industrial Relevance

While primarily studied in yeast models, β-1,6-glucan synthesis pathways are conserved in pathogenic fungi (e.g., Candida spp.), making Sup11p a potential antifungal drug target . No commercial therapeutic applications are currently reported.